Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13577660 | 0.85 | LMNA (0.41) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL13107567 | 0.82 | LMNA (0.33) | L3MBTL1MAPTLMNAHPGDMAOA | |
| SCHEMBL3442298 | 0.82 | MAOB (0.41) | MAPTTDP1MAOB | |
| SCHEMBL2146762 | 0.81 | LMNA (0.50) | L3MBTL1MAPTTDP1LMNAPTPN1 | |
| SCHEMBL3442225 | 0.81 | PDCD1 (0.48) | MAOB | |
| SCHEMBL10247270 | 0.80 | PTPN1 (0.49) | L3MBTL1MAPTMAPK1TDP1LMNA | |
| SCHEMBL5665324 | 0.79 | L3MBTL1 (0.43) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL25877526 | 0.78 | PTPN1 (0.48) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL25877949 | 0.78 | PTPN1 (0.45) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL17523247 | 0.78 | MAPT (0.51) | CCNB2CDK1CDK4CCNB1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824825-A4 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | MEDICURE INT INC (BB) | 2009-07-08 | — | — | EP | disclosed |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | MEDICURE INTERNATIONAL INC. (BB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | MEDICURE INTERNATIONAL INC. (BB) | 2008-12-11 | — | — | US | disclosed |
| EP-1824825-A1 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | Medicure International Inc. (BB) | 2007-08-29 | — | — | EP | disclosed |
| US-20060241083-A1 | Novel heteroaryl phosphonates as cardioprotective agents | MEDICURE INTERNATIONAL INC. (IN) | 2006-10-26 | — | — | US | disclosed |
| WO-2006045203-A1 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | MEDICURE INTERNATIONAL INC. (CA) | 2006-05-04 | — | — | WO | disclosed |
| US-20060094749-A1 | Substituted pyridoxines as anti-platelet agents | MEDICURE INTERNATIONAL INC. | 2006-05-04 | — | — | US | disclosed |
| EP-1606295-A1 | HETEROARYL PHOSPHONATES, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATMENT OF VARIOUS DISORDERS USING THEM | Medicure Inc. (CA) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004083222-A1 | NOVEL HETEROARYL PHOSPHONATES AS CARDIOPROTECTIVE AGENTS | MEDICURE INC. (CA) | 2004-09-30 | — | — | WO | disclosed |
| US-20040186077-A1 | Novel heteroaryl phosphonates as cardioprotective agents | MEDICURE INTERNATIONAL INC. (BB) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186077-A1 | Novel heteroaryl phosphonates as cardioprotective agents | TNNT2, TNNI3, ADRB3 | CCNB2 2567/4885CDK1 2036/4885CDK4 2284/4885 |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | PNPO, GP6, PFKP | CCNB2 827/4885CDK1 1560/4885CDK4 1200/4885 |
| US-20060094749-A1 | Substituted pyridoxines as anti-platelet agents | PNPO, GP6, PFKP | CCNB2 827/4885CDK1 1560/4885CDK4 1200/4885 |
| US-20060241083-A1 | Novel heteroaryl phosphonates as cardioprotective agents | TNNI3, TNNT2, FABP3 | CCNB2 3508/4885CDK1 2539/4885CDK4 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.